We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Too-big pharma

10 January 2017 By Robert Cyran

Drugmakers spend $50 bln a year on R&D, but the payoff keeps declining. The projected return for the dozen biggest-spending companies is now less than 4 pct, according to Deloitte. Valeant tried to slash outlays and jack up prices. But it went too far and made things worse.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)